Cancer immunology and immunotherapy are driving forces of research and development in
oncology, mostly focusing on CD8+ T cells and the tumor microenvironment. Recent …

Cytotoxic T cells are important effectors of anti-tumor immunity. While tumor killing is
ascribed to CD8+ T cell function, pre-clinical and clinical studies have identified intra …

Immune checkpoint inhibitors (ICIs) have made an indelible mark in the field of cancer
immunotherapy. Starting with the approval of anti-cytotoxic T lymphocyte-associated protein …

Cancer growth and progression are associated with immune suppression. Cancer cells
have the ability to activate different immune checkpoint pathways that harbor …

Recent years have seen significant efforts in understanding and modulating the immune
response in cancer. In this context, immunosuppressive cells, including regulatory T cells …

Checkpoint receptor blockers, known to act by blocking the pathways that inhibit immune
cell activation and stimulate immune responses against tumor cells, have been immensely …

Cancer is currently the second leading cause of death globally and is expected to be
responsible for approximately 9.6 million deaths in 2018. With an unprecedented …

Quantitative lymphocyte alterations are frequent in patients with cancer, and strongly impact
prognosis and survival. The development of cancers in immunosuppressed patients has …

Background Immune checkpoint inhibition (ICI) with anti-CTLA-4 and/or anti-PD-1
antibodies is standard treatment for metastatic melanoma. Anti-PD-1 (pembrolizumab …

The relationships between absolute lymphocyte counts (ALC), drug-related toxicities, and
clinical responses remain unclear in cancer patients treated with PD-1 (programmed cell …